RESEARCH TRIANGLE PARK, N.C., Aug. 24 /PRNewswire/ --
Incara Pharmaceuticals Corporation (Nasdaq: INCR) President and CEO, Clayton I. Duncan, was interviewed this morning to discuss the company's liver stem and precursor cell therapy program for the website CEOcast. The audio interview can be accessed over the internet at www.ceocast.com .
Liver stem and precursor cells are a subpopulation of cells in the liver that can differentiate into a variety of daughter cells that provide liver function. Incara is studying the use of transplanting human liver precursor cells for the treatment of a variety of liver diseases. The Company is completing preclinical studies and is evaluating alternatives for the cGMP cell purification process needed to perform clinical studies. During 2001, Incara plans to begin initial clinical studies of the injection of human hepatic precursor cells as a treatment for children with life-threatening inborn errors of metabolism and adults with chronic liver failure.
Incara Pharmaceuticals Corporation (www.incara.com ) develops innovative pharmaceutical products and treatments for major diseases afflicting large patient populations. The Company's three current programs include liver stem and precursor cell therapy for the treatment of liver failure, small molecule catalytic antioxidants for treatment of stroke and chronic bronchitis, and an ultra-low molecular weight heparin for the treatment of inflammatory bowel disease.
Incara's catalytic antioxidant program discovers and develops small molecule catalytic antioxidants for the treatment of CNS diseases, including stroke, and for treatment of chronic bronchitis. Assuming satisfactory completion of preclinical studies, Incara intends to initiate clinical trials in stroke with a catalytic antioxidant in mid 2001.
Incara has licensed OP2000, an ultra-low molecular weight heparin, for study as a once-daily treatment for inflammatory bowel disease (IBD). OP2000 has completed Phase 1 clinical trials conducted by Incara and the drug has been studied for another indication in over 150 subjects and patients in Europe with no significant unexpected side effects. Incara intends its next clinical trial for OP2000 to be a Phase 2/3 study at 28 medical centers nationwide in patients with ulcerative colitis, one of the two common forms of IBD.
The statements in this press release that are not purely statements of historical fact are forward-looking statements, and actual results may differ materially from those anticipated. These statements and other statements made elsewhere by the Company or its representatives, which are identified or qualified by words such as "likely," "will," "suggests," "expects," "might," "may," "believe," "could," "should," "would," "anticipates," or "plans," or similar expressions, are based on a number of assumptions that are subject to risks and uncertainties. Important factors that could cause results to differ include risks associated with the need to obtain funds for operations, uncertainties of scientific research, clinical trials and product development activities. These and other important risks are described in Incara's reports on Form S-1, Form 10-K, Form 10-Q and Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update the information in this release.
No comments:
Post a Comment